Compare SWMR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWMR | ALT |
|---|---|---|
| Founded | 2023 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.1M | 421.5M |
| IPO Year | 2026 | 2005 |
| Metric | SWMR | ALT |
|---|---|---|
| Price | $37.09 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 257.7K | ★ 3.8M |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $2,862.05 | N/A |
| Revenue Next Year | $177.93 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $25.75 | $2.56 |
| 52 Week High | $83.30 | $6.44 |
| Indicator | SWMR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 53.88 |
| Support Level | $34.42 | $2.65 |
| Resistance Level | $38.06 | $3.15 |
| Average True Range (ATR) | 3.50 | 0.17 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 24.01 | 43.75 |
Swarmer Inc is a provider of autonomous drone swarm software and AI solutions, specializing in vendor-agnostic technologies. It develops software platforms and artificial intelligence systems for defence applications, enabling military organisations to deploy and coordinate large-scale unmanned and autonomous systems. Its offerings include swarm coordination software, multi-domain unmanned systems integration, collaborative autonomy solutions, and command-and-control software for distributed robotic operations. Its key software and AI systems include: i) STYX AI Command & Control System, ii) MINAS Autonomy and Collaboration AI and iii) TRIDENT Embedded Drone Operating System. The company generates revenue through software license sales.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.